Treatment of patients with locally advanced, non-metastatic prostate cancer, as an alternative to surgical castration (see section 5.1). Treatment of metastatic prostate cancer. As adjuvant treatment to radiotherapy in patients with high-risk localised or locally advanced prostate cancer. As neoadjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced prostate cancer. As adjuvant treatment to radical prostatectomy in patients with locally advanced prostate cancer at high risk of disease progression. Treatment of endometriosis. Treatment of uterine fibroids prior to surgery or when surgery is not appropriate. As adjuvant treatment in combination with tamoxifen or an aromatase inhibitor, of endocrine responsive early stage breast cancer in women at high risk of recurrence who are confirmed as pre-menopausal after completion of chemotherapy (see sections 4.3, 4.4, 4.8 and 5.1).